A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

This study has been completed.
Information provided by:
Mylan Bertek Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: September 13, 2005
Last updated: December 15, 2005
Last verified: September 2005
The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.

Condition Intervention Phase
Drug: Nebivolol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension

Resource links provided by NLM:

Further study details as provided by Mylan Bertek Pharmaceuticals:

Primary Outcome Measures:
  • The change in average sitting diastolic blood pressure measured at trough drug plasma level at the end of the extension phase compared to baseline of NEB 202, NEB 302 or NEB 305.

Secondary Outcome Measures:
  • Change in the average
  • - sitting systolic blood pressure
  • - supine and standing systolic and diastolic blood pressure
  • - response rate of treatment groups
  • - AEs
  • - ECGs
  • - laboratory parameters
  • - heart rate

Estimated Enrollment: 845
Study Start Date: March 2002
Estimated Study Completion Date: September 2003
Detailed Description:
This was an international, multicenter parallel group, 9-month extension study with a 4-week follow-up phase to evaluate the long-term safety and efficacy of nebivolol administered orally once daily in patients with mild to moderate hypertension (defined as an average sitting diastolic blood pressure greater then or equal to 95 mmHg and less then or equal to 109 mmHg when untreated, based on entry into NEB 202, NEB 302 or NEB 305). Patients were permitted protocol-defined concomitant use of diuretic or calcium antagonist. After successful completion of one of the 3-month efficacy "feeder" studies, patients were eligible to continue nebivolol treatment in this 9-month extension study. Patients who completed the extension phase and received only nebivolol monotherapy during the extension phase were eligible to enter the 1-month follow-up phase.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • To enter the long-term treatment phase, patients must have successfully completed NEB 202, NEB 302, or NEB 305. To enter the 4-week follow-up phase, patients must have completed NEB-306 (extension phase) and received only nebivolol monotherapy treatment during NEB 306.

Exclusion Criteria:

  • Secondary hypertension
  • myocardial infarction or stroke
  • contraindications to beta-blocker therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00200499

United States, West Virginia
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
Mylan Bertek Pharmaceuticals
Study Director: Betty S. Riggs, MD, MBA Mylan Pharmaceuticals
  More Information

ClinicalTrials.gov Identifier: NCT00200499     History of Changes
Other Study ID Numbers: NEB306 
Study First Received: September 13, 2005
Last Updated: December 15, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Mylan Bertek Pharmaceuticals:

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Vasodilator Agents

ClinicalTrials.gov processed this record on May 25, 2016